



Press release

SHL announces Yuval Shaked as new CEO

Tel Aviv / Zurich, 15 January 2016 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) ("SHL"), a leading provider and developer of advanced personal telemedicine solutions, announced today that the Board of Directors has appointed Yuval Shaked as Chief Executive Officer effective March 2, 2016. He will replace Erez Alroy and Yariv Alroy, the acting Co-CEOs, who stepped down on January 15, 2016, to pursue other businesses, and stay committed as shareholders.

SHL's Chairman Oren Most said: "On behalf of the Board of Directors for SHL, I am happy to welcome Yuval Shaked to the team. He is an exceptional leader; his track record in diverse functions for global companies in the health care arena has been extraordinary. Yuval Shaked was chosen in a competitive selection process from a strong field of candidates. He brings a vast array of relevant experience to the organization and we are looking forward to him leading the company through continued solid growth and success."

Oren Most continued: "I thank Erez and Yariv Alroy for their long, fully committed service to SHL, for their contagious and invigorating enthusiasm. As closely aligned leaders, Erez and Yariv have carried SHL from its inception to a globally leading company in telemedicine services. Thanks to their contribution, the company is now in a strong position to make the next leap in its evolution."

Erez Alroy said: "I am honored to have been able to lead SHL with my brother Yariv for over a decade. SHL has been the "professional homebase" throughout our careers, and we are excited to stay committed to the company as shareholders. Yariv and I are delighted to be handing over the reins to Yuval Shaked, an outstanding leader."

Incoming CEO Yuval Shaked said: "I am honored to be offered the opportunity to lead this great company. SHL is a true innovator, with great people, a solid strategy and good momentum. I look forward to working with the management team, the Board of Directors, and all the employees of SHL to further build the company's franchise around the globe."

Yuval Shaked has been serving as the General Manager – Diagnostic Cardiology of GE Healthcare in the US from 2012, being responsible for P&L of the division and leading both on- and off-shore R&D and marketing teams conducting worldwide sales of devices and IT solutions in the cardiology field. During his service, Yuval Shaked has gained extensive experience in the telemedicine space. Prior thereto, Yuval Shaked held the positions of General Manager of the VersaMed Business of GE Healthcare in Israel from 2010 to 2012 and Global Marketing and EMEA Home Sales Manager of GE Healthcare from 2009 to 2010, as well as VP Operations of VersaMed in Israel (a company acquired by GE) from 2007 to 2009. Mr. Shaked holds a B.A. in Economics (summa cum laude) from Haifa University, as well as an MBA from Tel Aviv University.

Yoav Rubinstein, the Company's Senior Vice-President, Head of Global Business Development, has been appointed to manage the Company in the interim period.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end



users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit our web site at www.shl-telemedicine.com.

For further information please contact:

Martin Meier-Pfister, IRF Communications, Phone: +41 43 244 81 40, shl@irfcom.ch

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.